More on MRNA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $49.91 |
|
|||
| Open | $49.91 | ||||
| 52 Wk High | $0.52 | ||||
| 52 Wk Low | $0.08 | ||||
| Day High | $49.91 | ||||
| Day Low | $49.91 | ||||
| P/E | N/A | ||||
| EPS | $-3.80 | ||||
| Volume | 16,709 | ||||
- Moderna and Oxford receive UK authorization for Lynch syndrome cancer vaccine trial
- Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
- Form 4 Moderna, Inc. For: Jun 04 Filed by: Klinger Shannon Thyme
- Form 4 Moderna, Inc. For: Jun 05 Filed by: Mock James M
- Form 144 Moderna, Inc. Filed by: Klinger Shannon Thyme
- Form 4 Moderna, Inc. For: Jun 01 Filed by: Mock James M
- Form 4 Moderna, Inc. For: Jun 01 Filed by: Klinger Shannon Thyme
- Form 4 Moderna, Inc. For: Jun 01 Filed by: Hoge Stephen
- Moderna (MRNA) sees strong intraday gains
- Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
Entities mentioned with MRNA
- FDA | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Options | View Related Stories »
- Pre Market Movers | View Related Stories »
- Show More...
